Bergenheim A T, Henriksson R
Department of Neurosurgery, Umeå University Hospital, Sweden.
Clin Pharmacokinet. 1998 Feb;34(2):163-72. doi: 10.2165/00003088-199834020-00004.
Estramustine phosphate (estramustine phosphate sodium), a carbamate ester combining 17 beta-estradiol and nor-nitrogen mustard, is a cytotoxic drug used in the treatment of advanced prostatic carcinoma. Because of the radiosensitising effect of this drug there has been a recent increase in interest concerning estramustine phosphate and its clinical use. It has also been found that the early recommendations of drug administration together with food or milk were inappropriate, since calcium containing food and antacids hamper drug uptake. This may have obscured results from earlier clinical studies with estramustine phosphate. Estramustine phosphate is currently being re-evaluated for the treatment of other tumours such as glioma and mammary carcinoma. This review summarises the present relatively limited knowledge concerning the pharmacokinetic and pharmacodynamic aspects of estramustine phosphate and its metabolites.
磷酸雌莫司汀（磷酸雌莫司汀钠）是一种将17β - 雌二醇与去甲氮芥结合的氨基甲酸酯，是一种用于治疗晚期前列腺癌的细胞毒性药物。由于该药物的放射增敏作用，近期人们对磷酸雌莫司汀及其临床应用的兴趣有所增加。还发现早期关于与食物或牛奶一起给药的建议并不恰当，因为含钙食物和抗酸剂会妨碍药物吸收。这可能掩盖了早期磷酸雌莫司汀临床研究的结果。目前正在对磷酸雌莫司汀用于治疗其他肿瘤（如神经胶质瘤和乳腺癌）进行重新评估。本综述总结了目前关于磷酸雌莫司汀及其代谢物的药代动力学和药效学方面相对有限的知识。
